Atrial Arrhythmia, Atrial Fibrillation, Atrial Flutter, Atrial Tachycardia
Conditions
Keywords
Anticoagulants, Anticoagulation, Cardioversion, NOAC, DOAC
Brief summary
This single-center observational registry follows contemporary efficacy and short-term complications of elective electric cardioversion.
Interventions
PROCEDUREElectric cardioversion
Electric cardioversion in short sedation according to established clinical practice and indications
Sponsors
Institute for Clinical and Experimental Medicine
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Consecutive out-patients undergoing electric cardioversion for atrial fibrillation, atrial tachycardia, or typical atrial flutter
Exclusion criteria
* Unstable patients with acute conditions requiring unplanned hospitalization
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Acute major complications | Within 24 hours from the procedure | Major thromboembolic events or events related to cardioversion requiring unplanned hospitalisation (bleeding, severe bradycardia, anesthesia-related complications, heart failure etc) |
| Subacute major complications | 24 hours to 30 days after the procedure | Major thromboembolic events or events related to cardioversion requiring unplanned hospitalisation (bleeding, severe bradycardia, anesthesia-related complications, acute heart failure etc), evaluated by structured phone call. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Acute minor complications | Within 24 hours from the procedure | Minor procedure-related complications not requiring acute hospitalisation (asymptomatic bradycardia, post-anesthesia spasms) |
| Acute efficacy | Within 2 hours from the procedure | Presence of sinus rhythm on continous ECG (5-lead) monitoring |
Countries
Czechia
Outcome results
None listed